LabTech Systems Ltd (ASX: LBT), an Australian health care equipment and services company, and bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, announced today that they have signed an exclusive worldwide license agreement for LabTech Systems’ automated pre-poured media (PPM) streaker known as MicroStreak®.
Schweiz
bioMérieux Launches VIDAS® B·R·A·H·M·S PCT, a Procalcitonin Measurement Test Allowing Early Detection of Severe Bacterial Infections
30 März, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, today announces the launch of VIDAS® B·R·A·H·M·S PCT. This new, CE approved test, was developed following the licensing agreement signed with B·R·A·H·M·S, enabling bioMérieux to develop, produce and market a test for measuring procalcitonin (PCT) levels. The test is sensitive and specific, used in the early detection of severe bacterial infections (e.g. sepsis).
bioMérieux Receives Major Order from BML, Japan’s Biggest Laboratory Chain
06 März, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, announces today that it has received a major order from BML, Inc. (BioMedical Laboratories), the biggest Japanese private laboratory chain. bioMérieux will supply 28 VITEK® 2 XL to BML.
bioMérieux confirms its commitment to the fight against Hospital Acquired Infections
15 Februar, 2007
bioMérieux, a global leader in the field of in vitro diagnostics, confirms its commitment to the fight against Hospital Acquired Infections with the launch of three new products.
bioMérieux and ExonHit Therapeutics initiate their third diagnostic program
04 Januar, 2007
Screening of prostate cancer from blood. bioMérieux and ExonHit Therapeutics announce, today, the initiation of their third programme for the screening of cancer from blood. One of the goals is to assist physicians in deciding whether to proceed with surgery for prostate cancer.
bioMérieux launches VIDAS® Troponin I Ultra
07 Dezember, 2006
bioMérieux, a major player in the field of in vitro diagnostics, is reinforcing its commitment to combating cardiovascular diseases by launching VIDAS Troponin I Ultra, a first-line parameter in acute coronary syndrome diagnostics.
bioMérieux will be awarded up to €54.5 million by France’s Agence de l’Innovation Industrielle to pursue molecular biology research
24 November, 2006
bioMérieux today announced that it will be awarded up to €54.5 million over the next ten years by France’s Agence de l’Innovation Industrielle to help fund the “Advanced Diagnostics and New therapeutic Approaches” (ADNA) program, led by Mérieux Alliance. Of this amount, €25.6 million will be in the form of grants and €28.9 million in the form of loans. The financing is subject to approval by the European Union, which is expected to make a decision in the second quarter of 2007.
